Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib and Binimetinib in Neoadjuvant Melanoma
NCT04221438Phase 2Terminated
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Sep 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of encorafenib and binimetinib in melanoma, sponsored by ECOG-ACRIN Cancer Research Group. Primary endpoint: Pathologic Complete Response. Started Sep 2021; status: terminated.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04221438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04221438.